TriArm Therapeutics

About:

TriArm Therapeutics is a developer of cellular immunotherapy products intended for the treatment of cancer patients.

Top Investors: Lombard Odier, Panacea Venture, Panacea Venture, HT Capital, Viventures

Description:

TriArm Therapeutics is a cell therapy company formed by Panacea Venture with R&D operations in Germany, United States and Greater China region. The company focuses on the research and clinical transformation of CD19 CAR-T product using non-viral gene transfer technology, which greatly reduces the cost and time of cell therapy product preparation, enabling better tumor therapy outcome.

Total Funding Amount:

$80M

Headquarters Location:

Beijing, Beijing, China

Founded Date:

2018-01-01

Founders:

Jay Zhang, Jinhua Lu

Number of Employees:

11-50

Last Funding Date:

2021-09-27

IPO Status:

Private

Industries: